PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it. Resistance to cancer immunotherapy can be mediated by additional immune checkpoints. We hypothesized that co-...

Full description

Bibliographic Details
Main Authors: Haiping Jiang, Haiqing Ni, Pan Zhang, Xiaoli Guo, Min Wu, Haoran Shen, Jie Wang, Weiwei Wu, Zhihai Wu, Jiazheng Ding, Rong Tang, Shuaixiang Zhou, Bingliang Chen, Michael Yu, Hua Jing, Junjian Liu
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
pd-l1
lag-3
bispecific
cancer immunotherapy
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1943180

Internet

http://dx.doi.org/10.1080/2162402X.2021.1943180

Similar Items